References
- Tan TG, Mui E, Cong H et al. Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine28(23), 3977–3989 (2010).
- Brown CR, McLeod R. Class I MHC genes and CD8+ T cells determine cyst number in Toxoplasma gondii infection. J. Immunol.145, 3438–3441 (1990).
- Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-γ production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J. Immunol.146, 286–292 (1991).
- Kumar S, Miller LH, Quakyi IA et al. Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature334, 258–260 (1988).
- Kaufmann SHE, Follows GA, Munik ME. Immunity to intracellular bacteria. Mem. Inst. Oswaldo Cruz87, 91–94 (1992).
- McLeod R, Boyer K, Karrison T et al. Outcome of treatment for congenital toxoplasmosis, 1981–2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin. Infect. Dis.42, 1383–1394 (2006).
- McLeod R, Kieffer F, Sautter M, Hosten T, Pelloux H. Why prevent, diagnose and treat congenital toxoplasmosis? Mem. Inst. Oswaldo Cruz104, 320–344 (2009).
- Miller CM, Boulter NR, Ikin RJ, Smith NC. The immunobiology of the innate response to Toxoplasma gondii. Int. J. Parasitol.39, 23–39 (2009).
- Ryning FW, McLeod R, Maddox JC, Hunt S, Remington JS. Probable transmission of Toxoplasma gondii by organ transplantation. Ann. Intern. Med.90, 47–49 (1979).
- Eggers M, Boes-Fabian B, Ruppert T, Kloetzel PM, Koszinowski UH. The cleavage preference of the proteasome governs the yield of antigenic peptides. J. Exp. Med.182, 1865–1870 (1995).
- Carrington M, Colonna M, Spies T, Stephens JC, Mann DL. Haplotypic variation of the transporter associated with antigen processing (TAP) genes and their extension of HLA class II region haplotypes. Immunogenetics37, 266–273 (1993).
- Li S, Paulsson KM, Sjögren HO, Wang P. Peptide-bound major histocompatibility complex class I molecules associate with tapasin before dissociation from transporter associated with antigen processing. J. Biol. Chem.274, 8649–8654 (1999).
- Cresswell P, Bangia N, Dick T, Diedrich G. The nature of the MHC class I peptide loading complex. Immunol. Rev.172, 21–28 (1999).
- Blanchard N, Gonzalez F, Schaeffer M et al. Immunodominant, protective response to the parasite Toxoplasma gondii requires antigen processing in the endoplasmic reticulum. Nat. Immunol.9, 937–944 (2008).
- Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol.17, 51–88 (1999).
- Lund O, Nielsen M, Kesmir C et al. Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics55, 797–810 (2004).
- Reche PA, Reinherz EL. Definition of MHC supertypes through clustering of MHC peptide binding repertoires. In: Artificial Immune Systems, Proceedings. Springer Verlag, Berlin, Germany, 189–196 (2004).
- Sidney J, del Guercio MF, Southwood S et al. Several HLA alleles share overlapping peptide specificities. J. Immunol.154, 247–259 (1995).
- Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol.9, 1 (2008).
- Sette A, Sidney J, Livingston BD et al. Class I molecules with similar peptide-binding specificities are the result of both common ancestry and convergent evolution. Immunogenetics54, 830–841 (2003).
- Lundegaard C, Lund O, Buus S, Nielsen M. Major histocompatibility complex class I binding predictions as a tool in epitope discovery. Immunology130, 309–318 (2010).
- BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology106, 113–121 (2002).
- BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines – yesterday, today, and tomorrow. Lancet Infect. Dis.2, 425–431 (2002).
- Deliyannis G, Jackson DC, Ede NJ et al. Induction of long-term memory CD8+ T cells for recall of viral clearing responses against influenza virus. J. Virol.76, 4212–4221 (2002).
- Livingston BD, Alexander J, Crimi C et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J. Immunol.162, 3088–3095 (1999).
- Alexander J, Sidney J, Southwood S et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity1, 751–761 (1994).
- Ishioka GY, Fikes J, Hermanson G et al. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J. Immunol.162, 3915–3925 (1999).
- Persing DH, Coler RN, Lacy MJ et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol.10, S32–S37 (2002).
- Botten J, Alexander J, Pasquetto V et al. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J. Virol.80, 8351–8361 (2006).
- Nielsen M, Lundegaard C, Lund O, Keşmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics57, 33–41 (2005).
- Peters B, Bulik S, Tampe R, Endert PMV, Holzhutter HG. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J. Immunol.171, 1741–1749 (2003).
- Nielsen M, Lund O, Buus S, Lundegaard C. MHC class II epitope predictive algorithms. Immunology DOI: 10.1111/j.1365–2567.2010.03268.x (2010) (Epub ahead of print).
- Rapin N, Hoof I, Lund O, Nielsen M. The MHC motif viewer: a visualization tool for MHC binding motifs. Curr. Protoc. Immunol.18(18), 17 (2010).